about
Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myelomaEvidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapieImplications of heterogeneity in multiple myeloma.PBOX-15, a novel microtubule targeting agent, induces apoptosis, upregulates death receptors, and potentiates TRAIL-mediated apoptosis in multiple myeloma cellsPrognostic value and efficacy evaluation of novel drugs for cytogenetic aberrations in multiple myeloma: a meta-analysis.Effectiveness of targeted therapy as monotherapy or combined therapy in patients with relapsed or refractory multiple myeloma: a systematic review and meta-analysis.Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasoneSmall Molecule MYC Inhibitor Conjugated to Integrin-Targeted Nanoparticles Extends Survival in a Mouse Model of Disseminated Multiple Myeloma.Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders.Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized studyRelationship between elevated immunoglobulin free light chain and the presence of IgH translocations in multiple myelomaPatterns of relapse and progression in multiple myeloma patients after auto-SCT: implications for patients' monitoring after transplantation.Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study.Clinical significance of granule-containing myeloma cells in patients with newly diagnosed multiple myeloma.Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelinesA common variant within the HNF1B gene is associated with overall survival of multiple myeloma patients: results from the IMMEnSE consortium and meta-analysis.The Belgian 2010 consensus recommendations for the treatment of multiple myeloma.Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2.Treatment of newly diagnosed multiple myeloma in transplant-eligible patients.Genomic stratification of multiple myeloma treated with novel agents.Understanding the molecular biology of myeloma and its therapeutic implications.Aberrant microRNA expression in multiple myeloma.IMWG consensus on risk stratification in multiple myeloma.Application of an immune-magnetic cell sorting method for CD138-positive plasma cells in FISH analysis of multiple myeloma.Management of Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma.Prognostic value of PINI index in patients with multiple myeloma.Carbamazepine and hematological malignanciesIncorporation of the bone marker carboxy-terminal telopeptide of type-1 collagen improves prognostic information of the International Staging System in newly diagnosed symptomatic multiple myeloma.Bortezomib-based induction improves progression-free survival of myeloma patients harboring 17p deletion and/or t(4;14) and overcomes their adverse prognosis.
P2860
Q33573752-575E379B-5817-45C1-BF71-AA52C0A1B761Q33884167-BF973990-BA9D-4DA2-9BCE-19ADB7E09032Q33914824-C7251DE0-B2D0-4EA0-8216-8EF6C2DD2E59Q34543759-9F8035A8-E5C9-496D-81F6-4C76CF961CE1Q34769841-F5A8209F-D124-4FCD-B6B6-8BF40D5F4CC5Q35104606-3C463E61-75CE-4B16-8959-367B0BE38A98Q35485758-DF1C7EC0-F983-4A51-A516-C7DC2F950ADEQ35590573-8952197D-E210-44AC-9375-B5AA27B9EF44Q36133050-47D38456-B723-4309-9A19-3FE118B96B2EQ36382493-81458C8E-F470-4026-9895-47F5962EA8E1Q36572310-F7F83017-45AD-4640-8E8C-1621A01976E0Q36675330-A239A5E1-E93D-4190-BC28-1372CDD08B3AQ37397995-BE9D7275-4282-4AFC-B79A-F7580F9696ABQ37429898-E6E51ECA-C910-4DC4-9759-EC80D4018EFFQ37454445-728170F6-A1B6-4BA4-A79A-057D52CA42BBQ37644812-DE4FBA26-E40A-4583-A1FE-84B2EB8CB99DQ37800884-50CEDD68-7012-4679-8734-9C230239A649Q37835572-F3B45B93-F67F-44FD-963F-0CD30E023638Q37851855-6EFC13CF-B977-4032-A465-8BCAB4D052EDQ37913346-0C5C0F0C-F7AE-4E3F-9524-2927986A6162Q38065305-69D94082-A227-45F5-97DD-8F1CC13B546CQ38099048-E01131F5-B32D-418B-B619-F660B999FDC8Q38131380-C4504E12-5B13-4F06-9E79-4C45392C7868Q38403024-397C20FC-E715-4A08-918C-9AE5A7198B76Q38970595-7C6D9A0E-FE73-417A-BCBE-B2285CC0905FQ39681433-8D22114E-B047-4F64-BAEB-AD9EFEB3A6F5Q42771780-B2C7FEE2-683D-459A-ADB4-AAC42B6A71EFQ46246952-265F3A21-598A-4F24-AB53-2A5E3A6E6BADQ46432419-09F5F3A4-B12A-407E-BB63-245023DF791E
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Role of genetics in prognostication in myeloma.
@en
Role of genetics in prognostication in myeloma.
@nl
type
label
Role of genetics in prognostication in myeloma.
@en
Role of genetics in prognostication in myeloma.
@nl
prefLabel
Role of genetics in prognostication in myeloma.
@en
Role of genetics in prognostication in myeloma.
@nl
P1476
Role of genetics in prognostication in myeloma.
@en
P304
P356
10.1016/J.BEHA.2007.08.005
P577
2007-12-01T00:00:00Z